Patients in the UK and Singapore could gain faster access to cutting-edge healthcare innovations under a new partnership bringing two globally respected regulators together with one of the world’s leading biotech creators.
As part of this first-of-its-kind regulatory collaboration between the UK’s MHRA and Singapore’s Health Sciences Authority (HSA) (with Flagship Pioneering as its first partner), companies will have a coordinated pathway enabling them to engage with both regulators at the same time.
- Under the new corridor, developers will be able to seek early, informal joint advice, helping them plan ahead and design better clinical trials, avoid duplication and cut delays.
- The aim is to speed up patient access to breakthrough therapies in high-impact areas such as:
- cancer
- neurodegenerative disease
- obesity, rare diseases and
- advanced diagnostics – without compromising on safety.
- The partnership will help both countries horizon scan for emerging technologies and therapeutic modalities, learn from each other’s regulatory approaches and boost regulatory innovation, strengthening their position as global hubs for life science investment.
About Flagship Pioneering
Flagship Pioneering, a scientific innovation engine that generates transformative platforms and products, will be the first company to access the new Regulatory Innovation Corridor, due to its strategic commitment with both countries.
- Its early-stage programmes across an ecosystem of more than 40 companies span a broad range of new therapeutic modalities that could inform regulatory paradigm shifts on the horizon.
- This includes next-generation genetic medicines, precision immunology and digital health, providing both countries visibility into a strong pipeline of potential breakthroughs to prepare to assess safely and innovatively.
Source: MHRA